Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report released on Saturday. The brokerage issued a sell rating on the stock.

CANF has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, November 12th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st.

Can-Fite BioPharma Trading Down 2.5 %

NYSE:CANF opened at $1.55 on Friday. The stock’s 50 day simple moving average is $1.72 and its 200-day simple moving average is $2.26. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69. The firm has a market cap of $5.49 million, a P/E ratio of -0.87 and a beta of 1.36.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC boosted its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned approximately 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent filing with the SEC. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.